Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q4 FY20 results · Jan–Mar 2020
Solara Active Pharma Sciences reported revenue from operations of ₹296.77 crore (down 23.0% from Q4 FY19) and net profit of ₹17.81 crore (down 32.0% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 296.77 | 385.31 | −23.0% | 343.68 | −13.6% |
| Other income | 12.13 | 6.63 | +83.0% | 6.08 | +99.5% |
| Total income | 308.90 | 391.94 | −21.2% | 349.76 | −11.7% |
| Profit before tax | 17.90 | 26.16 | −31.6% | 41.33 | −56.7% |
| Net profit for the period | 17.81 | 26.20 | −32.0% | 41.33 | −56.9% |
| Attributable to shareholders of the company | 14.26 | 26.32 | −45.8% | 41.32 | −65.5% |
| EPS, basic (₹) | 6.78 | 10.17 | −33.3% | 16.00 | not comparable |
| Net margin (%) | 6.0 | 6.8 | 12.0 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 296.77 | 380.10 | −21.9% | 343.68 | −13.6% |
| Other income | 12.11 | 3.63 | +233.6% | 6.10 | +98.5% |
| Total income | 308.88 | 383.73 | −19.5% | 349.78 | −11.7% |
| Profit before tax | 18.18 | 28.44 | −36.1% | 41.21 | −55.9% |
| Net profit for the period | 18.18 | 27.06 | −32.8% | 41.21 | −55.9% |
| EPS, basic (₹) | 6.92 | 10.48 | −34.0% | 15.95 | not comparable |
| Net margin (%) | 6.1 | 7.1 | 12.0 |
Consolidated
- Filed with BSE
- 08 May 2020, 14:57 IST
- Board meeting
- 07 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 May 2020, 14:57 IST
- Board meeting
- 07 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE